A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

← catalyst calendar

NCT07059845 · readout ≤ 896 d

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

400estimated

Sites

Countries

Australia, Belgium, Czechia +5

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-11-13

actual

When the study began enrolling

Primary completion

Jan 2029

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Jan 2029

estimated

The whole study's end, after follow-up

First posted

2025-07-11

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-04

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Ovarian Cancer

Interventions

Drug: Mirvetuximab Soravtansine
Drug: Bevacizumab
Drug: Carboplatin

Primary outcomes

what the primary-completion date above is the date OF

Substudy 1, 2, and 3: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) (any grade, Grade >= 3)